346 related articles for article (PubMed ID: 27149447)
1. Benign Prostatic Hyperplasia and the Risk of Prostate Cancer and Bladder Cancer: A Meta-Analysis of Observational Studies.
Dai X; Fang X; Ma Y; Xianyu J
Medicine (Baltimore); 2016 May; 95(18):e3493. PubMed ID: 27149447
[TBL] [Abstract][Full Text] [Related]
2. Benign prostatic hyperplasia and subsequent risk of bladder cancer.
Kang D; Chokkalingam AP; Gridley G; Nyren O; Johansson JE; Adami HO; Silverman D; Hsing AW
Br J Cancer; 2007 May; 96(9):1475-9. PubMed ID: 17473820
[TBL] [Abstract][Full Text] [Related]
3. The Association between Dietary Inflammatory Potential and Urologic Cancers: A Meta-analysis.
Dai YN; Yi-Wen Yu E; Zeegers MP; Wesselius A
Adv Nutr; 2024 Jan; 15(1):100124. PubMed ID: 37940476
[TBL] [Abstract][Full Text] [Related]
4. Benign prostatic hyperplasia is a significant risk factor for bladder cancer in diabetic patients: a population-based cohort study using the National Health Insurance in Taiwan.
Tseng CH
BMC Cancer; 2013 Jan; 13():7. PubMed ID: 23286275
[TBL] [Abstract][Full Text] [Related]
5. Pygeum africanum for benign prostatic hyperplasia.
Wilt T; Ishani A; Mac Donald R; Rutks I; Stark G
Cochrane Database Syst Rev; 2002; 1998(1):CD001044. PubMed ID: 11869585
[TBL] [Abstract][Full Text] [Related]
6. Association of benign prostatic hyperplasia and subsequent risk of bladder cancer: an Asian population cohort study.
Fang CW; Liao CH; Wu SC; Muo CH
World J Urol; 2018 Jun; 36(6):931-938. PubMed ID: 29427001
[TBL] [Abstract][Full Text] [Related]
7. An Updated Meta-analysis on the Risk of Urologic Cancer in Patients with Systemic Lupus Erythematosus.
Yeo J; Seo MS; Hwang IC; Shim JY
Arch Iran Med; 2020 Sep; 23(9):614-620. PubMed ID: 32979908
[TBL] [Abstract][Full Text] [Related]
8. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
9. The recurrence and progression risk after simultaneous endoscopic surgery of urothelial bladder tumour and benign prostatic hyperplasia: a systematic review and meta-analysis.
Sari Motlagh R; Mori K; Miura N; Quhal F; Aydh A; Laukhtina E; Pradere B; Karakiewicz PI; Enikeev DV; Deuker M; Shariat SF
BJU Int; 2021 Feb; 127(2):143-152. PubMed ID: 32564458
[TBL] [Abstract][Full Text] [Related]
10. Lycopene for the prevention and treatment of benign prostatic hyperplasia and prostate cancer: a systematic review.
Ilic D; Misso M
Maturitas; 2012 Aug; 72(4):269-76. PubMed ID: 22633187
[TBL] [Abstract][Full Text] [Related]
11. The Potential Role of MicroRNAs as Biomarkers in Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis.
Greco F; Inferrera A; La Rocca R; Navarra M; Casciaro M; Grosso G; Gangemi S; Ficarra V; Mirone V
Eur Urol Focus; 2019 May; 5(3):497-507. PubMed ID: 29398458
[TBL] [Abstract][Full Text] [Related]
12. Cernilton for benign prostatic hyperplasia.
Wilt T; Mac Donald R; Ishani A; Rutks I; Stark G
Cochrane Database Syst Rev; 2000; (2):CD001042. PubMed ID: 10796739
[TBL] [Abstract][Full Text] [Related]
13. Synergistic interaction of benign prostatic hyperplasia and prostatitis on prostate cancer risk.
Hung SC; Lai SW; Tsai PY; Chen PC; Wu HC; Lin WH; Sung FC
Br J Cancer; 2013 May; 108(9):1778-83. PubMed ID: 23612451
[TBL] [Abstract][Full Text] [Related]
14. Family history of cancer and the risk of prostate cancer and benign prostatic hyperplasia.
Negri E; Pelucchi C; Talamini R; Montella M; Gallus S; Bosetti C; Franceschi S; La Vecchia C
Int J Cancer; 2005 Apr; 114(4):648-52. PubMed ID: 15578689
[TBL] [Abstract][Full Text] [Related]
15. Coffee consumption and urologic cancer risk: a meta-analysis of cohort studies.
Huang TB; Guo ZF; Zhang XL; Zhang XP; Liu H; Geng J; Yao XD; Zheng JH
Int Urol Nephrol; 2014 Aug; 46(8):1481-93. PubMed ID: 24677003
[TBL] [Abstract][Full Text] [Related]
16. Preliminary study of the frequency of benign prostatic hyperplasia and prostatic cancer in China.
Gu FL; Xia TL; Kong XT
Urology; 1994 Nov; 44(5):688-91. PubMed ID: 7526525
[TBL] [Abstract][Full Text] [Related]
17. Occupational risk factors for prostate cancer and benign prostatic hyperplasia: a case-control study in Western Australia.
Fritschi L; Glass DC; Tabrizi JS; Leavy JE; Ambrosini GL
Occup Environ Med; 2007 Jan; 64(1):60-5. PubMed ID: 17018583
[TBL] [Abstract][Full Text] [Related]
18. Metformin reduces prostate cancer risk among men with benign prostatic hyperplasia: A nationwide population-based cohort study.
Kuo YJ; Sung FC; Hsieh PF; Chang HP; Wu KL; Wu HC
Cancer Med; 2019 May; 8(5):2514-2523. PubMed ID: 30968600
[TBL] [Abstract][Full Text] [Related]
19. Indications for and use of nonsteroidal antiinflammatory drugs and the risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.
Schenk JM; Calip GS; Tangen CM; Goodman P; Parsons JK; Thompson IM; Kristal AR
Am J Epidemiol; 2012 Jul; 176(2):156-63. PubMed ID: 22759721
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of the association between the inflammatory potential of diet and urologic cancer risk.
Lu DL; Ren ZJ; Zhang Q; Ren PW; Yang B; Liu LR; Dong Q
PLoS One; 2018; 13(10):e0204845. PubMed ID: 30273380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]